ATOMO DIAGNOSTICS LIMITED — AGM Information 2024

Nov 14, 2024

15 November 2024

==> picture [75 x 73] intentionally omitted <==

ASX Announcement

2024 Annual General Meeting – Chairman’s Address

In accordance with ASX Listing Rule 3.13.3, Atomo Diagnostics Limited ( Atomo) attaches the Chairman’s Address to be delivered at Atomo’s 2024 Annual General Meeting.

For more information, please contact:

John Kelly Managing Director & CEO e. john.kelly@atomodiagnostics.com p. +61 401 922 279

This announcement was authorised by the Managing Director & CEO on behalf of the Board.

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684

==> picture [75 x 73] intentionally omitted <==

On behalf of my fellow directors, I welcome you warmly to Atomo Diagnosfics’ (Atomo) Annual General Meefing for 2024.

date. I will invite John Kelly, Atomo’s CEO and Managing Director, to discuss both in further detail.

I will then ask you to consider several resolufions we have put forward. The Board highly values shareholder feedback and parficipafion in our AGM.

The Board is parficularly mindful of the Resolufion concerning Remunerafion, which received a strike at our last AGM. Reflecfing shareholder feedback, you will see that this year’s Resolufion on Remunerafion is materially different. I will spend fime on this when we reach Resolufions.

Your Company confinues to parficipate extensively in the adopfion of rapid tesfing as a crifical means of early infecfion detecfion. Advocacy for such tesfing is shared with the Federal Government amongst public and private agencies globally. Locally, such support sees the Federal Government funding free distribufion of Atomo’s HIV self-test through vending machines.

Decentralised tesfing serves to empower and scale. Individuals are empowered through having userfriendly devices that test for specific condifions with immediate results. Similarly, decentralised tesfing seftings screen effecfively and early, scaling the health system’s capacity to respond to community health needs.

Throughout last financial year and so far this year, we have seen the confinuing adopfion of rapid tests by both consumers and professional users. With our partner Newfoundland Healthcare, Atomo’s tests are on the shelves of TESCO and Boots, while through our direct sales, you can find our tests in local pharmacies and through vending machines care of a Federal funded scheme.

Sales of our plafforms under OEM+ contracts serve to scale Atomo’s technologies across different tests, including LUMOS’ FebriDX’s bacterial test and NG Biotech’s pregnancy test.

Looking ahead, we announced a Federal Government grant for Atomo to support the development of the world’s first rapid test for detecfion of acfive syphilis in collaborafion with the Burneft Insfitute. We are also delighted with BARDA’s announced support for LUMOS’ Pascal based FebriDx to seek a CLIA waiver to allow widespread distribufion in the US.

For those who are more recent Atomo shareholders, our warm welcome. Let me summarise what we do in rapid diagnosfics.

Atomo develops, commercialises, and supplies finished rapid diagnosfic tests and devices for rapid diagnosfic tests. We also partner with clinical partners to develop new tests and launch them into global markets. Our technology supports tesfing to detect infecfious diseases, chronic health condifions, and consumer wellness.

Atomo parficipates in three idenfified markets in developing and commercialising diagnosfic devices. These comprise infecfious disease tesfing, OEM+ devices, and sexual health and wellness.

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684

==> picture [75 x 73] intentionally omitted <==

Each of these markets involves Atomo's scale deployment of our patented technologies, often through partnering.

Atomo’s HIV Test leads our work in infecfious diseases. Demand spans Global Health Programmes and increasingly developed consumer markets. We extend across B2B sales in our OEM business and B2C through direct and partnered sales. As an example, we are delighted to have our HIV Self-Test supplied through Tesco Supermarkets and Boots pharmacies in the UK

In global health, our confinuing relafionship with Viatris Inc. sees growing in-country approvals for the sale of our HIV tests, especially amongst developing countries. As partners, during the year, we supplied Atomo plafform devices to NG Biotech, Access Biotech, and Lumos Diagnosfics to house support their proprietary clinical rapid diagnosfic tests.

Turning to our financial management, I menfioned that Atomo’s change in year-on-year revenues and sales mix reflected the overall market demand reducfion with the pandemic passing. Our corresponding ramp-up is in the producfion and delivery of our patented products.

The Board and Execufives exercise appropriate care in financial management, priorifising revenue growth and judicious regard for spending. The lafter is focused very much on supporfing the promofion and delivery of exisfing Atomo products. We confinue to work with the Company to ensure efficiency and benefit from reduced operafing costs, including reduced Board costs. John will talk through these changes.

To this end, the Board very much acknowledges the considerable efforts across the Execufive team and the wider Atomo workplace to seek efficiency in our acfivifies. I am pleased to report that these efforts are underway, and concurrently, we see strong posifive employee engagement through our workplace surveys.

On behalf of Atomo’s Board and Management, we gratefully acknowledge the fireless efforts of those who provide services and advice to Atomo – George Sidis and Richard Sokolov at IDE. Mathew Watkins and Kiara Ferraro, who provide Company Secretary services through Vistra Australia, and Gareth Few of BDO.

Atomo’s Board of Directors shares substanfial commercial, governance, and industry experience across the crifical aspects of our business. Among the Board’s priorifies is ensuring we have the capabilifies and domain experfise to govern our global business effecfively.

our People, Culture, and Remunerafion Commiftee, and Paul chairs Audit and Risk, which are pillars of our corporate governance. I sit on both Commiftees.

In keeping with Atomo's board process, you will shortly be asked to consider Deborah for re-elecfion to the Board. Along with fellow Directors and Execufives, I value Deborah’s contribufion greatly and strongly endorse her re-elecfion.

In closing, I share the Board’s strong recognifion of the Atomo team’s commitment to developing and implemenfing the Company’s strategy while making sense of and realising new opportunifies.

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684

==> picture [75 x 73] intentionally omitted <==

The decentralisafion of health services, diagnosfics and care confinues to evolve. The adopfion of rapid diagnosfics has changed users’ behaviours and expectafions of tesfing by locafion, speed to results and fimelier prescripfion. These changes align with Atomo’s proven competencies and focus on developing tests addressing unmet consumer needs. Atomo's compefifive posifioning draws from our product and commercialisafion experfise. We are excited about this year and those ahead. I welcome John to talk about what we are up to in further detail. Thank you for your enthusiasfic support, quesfions, and interest in Atomo.

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684